Terms: = Uterine cancer AND PPP2R1A, PR65A, 5518, ENSG00000105568, MGC786, P30153 AND Diagnosis
4 results:
1. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
2. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract] [Full Text] [Related]
3. A Selected Immunohistochemical Panel Aids in Differential diagnosis and Prognostic Stratification of Subtypes of High-grade Endometrial Carcinoma: A Clinicopathologic and Immunohistochemical Study at a Single Institution.
Taskin OÇ; Onder S; Topuz S; Sozen H; Sen F; Ilhan R; Yavuz E
Appl Immunohistochem Mol Morphol; 2017; 25(10):696-702. PubMed ID: 27093454
[TBL] [Abstract] [Full Text] [Related]
4. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract] [Full Text] [Related]